Cagrilintide/semaglutide
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglu
Novo Nordisk · Phase 2 · Completed · Enrollment 626
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CagriSema | n/r | n/r | n/r | n/r |
| Semaglutide | n/r | n/r | n/r | n/r |
| Cagrilintide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- CagriSema: endpoint not reported
- Semaglutide: endpoint not reported
- Cagrilintide: endpoint not reported
- Placebo: endpoint not reported